BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability ReportBusiness Wire • 6 days ago
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Companys strategy, the progress it...
Share to Feed
Key Insights Given the large stake in the stock by institutions, BeiGene's stock price might be vulnerable to their...
Clear Harbor Asset Management LLC acquired a new stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange...
This is a signal that BGNE's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
This price move could indicate a change in the trend, and may be a sell signal for investors...
This is a Bearish indicator signaling BGNE's price could decline from here. Traders may explore shorting the stock or put options...
This price move could be a signal that BGNE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...
BeiGene (NASDAQ:BGNE Get Free Report) had its target price increased by JPMorgan Chase Co. from $184.00 to $186.00 in a research note issued on Tuesday, Benzinga reports. The firm...
BeiGene, Ltd. (NASDAQ:BGNE Get Free Report) CEO John Oyler sold 37,668 shares of the firms stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an...
FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy. Tevimbra's efficacy was demonstrated in the RATIONALE 302 trial with...